YOU ARE NOT FACING THIS ALONE

MAVYRET® PATIENT SUPPORT

Welcome to MAVYRET Patient Support

With MAVYRET Patient Support, you have dedicated one-on-one Nurse Ambassador* support every step of the way.

Your Nurse Ambassador can help you:

- Learn more about your condition and how MAVYRET works
- Identify possible ways you can save
- Make sense of your insurance coverage
- Prepare for conversations with your doctor

You can expect a call from your Nurse Ambassador within 1 business day (the call may come from any area code). Keep an eye out for their call.

To learn more, call 1-877-628-9738, or visit https://www.mavyret.com/patient-support

*Nurse Ambassadors are provided by AbbVie and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

For more information about AbbVie's privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.

Please see Important Safety Information on page 2.
Please see full Prescribing Information for additional information, including Patient Information or visit www.rxabbvie.com, and discuss with your doctor.

abbvie

MAVYRET®
glecaprevir/pibrentasvir
100 mg/40 mg tablets

Use and Important Safety Information

USE

MAVYRET is a prescription medicine used to treat adults and children 3 years of age and older with chronic (lasting a long time) hepatitis C virus (hep C):

- Genotypes (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis
- Or GT 1 infection and have been previously treated with a regimen that contained a hep C NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about MAVYRET?

Hepatitis B virus (hep B) reactivation: Before starting treatment with MAVYRET, your doctor will do blood tests to check for hep B infection. If you have ever had hep B infection, hep B could become active again during or after treatment for hep C with MAVYRET. Hep B that becomes active again (called reactivation) may cause serious liver problems, including liver failure and death. Your doctor will monitor you if you are at risk for hep B reactivation during treatment and after you stop taking MAVYRET.

Do not take MAVYRET if you:

- Have certain liver problems
- Are taking the medicines atazanavir or rifampin

What should I tell my doctor before taking MAVYRET?

- If you have had hep B infection, have liver problems other than hep C infection, have HIV-1 infection, have had a liver or a kidney transplant, and all other medical conditions.
- If you are pregnant or plan to become pregnant, or if you are breastfeeding or plan to breastfeed. It is not known if MAVYRET will harm your unborn baby or pass into your breast milk. Talk to your doctor about the best way to feed your baby if you take MAVYRET.
- **About all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. MAVYRET and other medicines may affect each other. This can cause you to have too much or not enough MAVYRET or other medicines in your body. This may affect the way MAVYRET or your other medicines work or may cause side effects.
- **Do not start taking a new medicine without telling your doctor.** Your doctor can tell you if it is safe to take MAVYRET with other medicines.

What are the possible side effects of MAVYRET?

- **In people who had or have advanced liver problems before starting treatment with MAVYRET, there is a rare risk of worsening liver problems, liver failure, and death.** Your doctor will check you for signs and symptoms of worsening liver problems during treatment with MAVYRET. Tell your doctor right away if you have any of the following: nausea; tiredness; yellowing of your skin or white part of your eyes; bleeding or bruising more easily than normal; confusion; dark, black, or bloody stool; loss of appetite; diarrhea; dark or brown (tea-colored) urine; swelling or pain on the upper right side of your stomach area (abdomen); sleepiness; vomiting of blood; or lightheadedness.
- The most common side effects of MAVYRET are headache and tiredness.

These are not all the possible side effects of MAVYRET. Call your doctor for medical advice about side effects.

This is the most important information to know about MAVYRET. For more information, talk to your doctor or healthcare provider.

MAVYRET oral pellets are dispensed in unit-dose packets. Each packet contains 50 mg glecaprevir/20 mg pibrentasvir.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for additional information, including Patient Information or visit www.rxabbvie.com, and discuss with your doctor.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

abbvie

US-MAVY-230176 September 2023

MAVYRET®
glecaprevir/pibrentasvir
100 mg/40 mg tablets

MAVYRET® PATIENT SUPPORT

Enrollment Form

MHC-103123-A10

1. Once completed, please fax this form to MAVYRET Patient Support **(1-866-938-6696)**.
2. Give your patient the MAVYRET Patient Support Welcome Sheet located on the first page of this form, and the Patient Information.
   Questions? Call 1-877-MAVYRET (1-877-628-9738).

All fields marked with an asterisk (*) are required. The healthcare provider (HCP) and the patient or legally authorized person should fill out this form before leaving the office.

1 PATIENT INFORMATION To be filled out by patient or legally authorized person. Please print clearly.

*First Name: _____ *Last Name: _____ *Date of Birth: _____

Gender: ☐ Male ☐ Female ☐ Other

*Address: _____ *City: _____ *State: _____ *ZIP: _____

*Home Phone #: _____ *Mobile Phone #: _____ *Email Address: _____

Best time to call (Monday-Friday): ☐ Anytime ☐ Morning ☐ Afternoon ☐ Evening

IF A LEGALLY AUTHORIZED PERSON IS COMPLETING THE FORM ON BEHALF OF THE PATIENT, PLEASE FILL IN THE FOLLOWING LINES:

First Name: _____ Last Name: _____

Relationship to Patient: _____ Phone #: _____

By enrolling, you may receive your own Nurse Ambassador provided by AbbVie. Nurse Ambassadors are provided by AbbVie and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

☐ I consent to the collection, use, and disclosure of my health-related personal data to receive communications from AbbVie regarding its products, programs, services, clinical trials, research opportunities and for online targeted advertising, as further described in the "How we may use Personal Data," "How we disclose Personal Data," and "Cookies and similar tracking and data collection technologies" sections of our Privacy Notice. My consent is required to process sensitive personal data under certain privacy laws, and I have the right to withdraw my consent by visiting "Your Privacy Choices" on AbbVie's website.

For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit https://abbv.ie/PrivacyPatient.

Through my submission of the MAVYRET Patient Support enrollment form, I consent to the collection, use, and disclosure of my personal health data, as described in the Privacy Notice above and in AbbVie's Privacy Notice in the "How We May Disclose Personal Data" section. My consent is required to process sensitive personal data under certain privacy laws, and I have the right to withdraw my consent by visiting "Your Privacy Choices" on AbbVie's website.

For healthcare provider (HCP) use only

2 PRESCRIBER INFORMATION To be completed by prescriber.

*Prescriber Name: _____ *NPI #: _____

Address: _____ City: _____ State: _____ ZIP: _____

Office Contact Name: _____ *Office Phone #: _____

Office Contact Email Address: _____ *Office Fax #: _____

Patient Diagnosis: ☐ Hepatitis C

IMPORTANT INFORMATION: By submitting this form, you are referring the above patient to AbbVie's patient support program to determine eligibility and receive support related to an AbbVie product. Please share this information with your patient.

For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties visit https://abbv.ie/PrivacyHCP.

Please see Important Safety Information on page 4.
Please see full Prescribing Information, including BOXED WARNING for Hepatitis B virus reactivation, for additional information or visit www.rxabbvie.com.

abbvie

MAVYRET® glecaprevir/pibrentasvir 100 mg/40 mg tablets

Indication and Important Safety Information

INDICATION[1]

MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.

IMPORTANT SAFETY INFORMATION[1]

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV: Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and posttreatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

CONTRAINDICATIONS

- MAVYRET is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or those with any history of prior hepatic decompensation.
- MAVYRET is contraindicated with atazanavir or rifampin.

WARNINGS AND PRECAUTIONS

Risk of Hepatic Decompensation/Failure in Patients with Evidence of Advanced Liver Disease

- Postmarketing cases of hepatic decompensation/failure, some fatal, have been reported in patients treated with HCV NS3/4A protease inhibitor–containing regimens, including MAVYRET. The median time to onset for MAVYRET was 27 days. The majority had moderate or severe hepatic impairment prior to initiating therapy, including some with compensated cirrhosis at baseline but with a prior decompensation event. Rare cases were reported in patients without cirrhosis or with compensated cirrhosis; many of these patients had evidence of portal hypertension. In patients with compensated cirrhosis or evidence of advanced liver disease, perform hepatic laboratory testing as clinically indicated; and monitor for signs and symptoms of hepatic decompensation, such as the presence of jaundice, ascites, hepatic encephalopathy, and variceal hemorrhage. Discontinue MAVYRET in patients who develop evidence of hepatic decompensation/failure.

Risk of Reduced Therapeutic Effect Due to Concomitant Use of MAVYRET with Certain Drugs

- Carbamazepine, efavirenz, and St. John's Wort may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect of MAVYRET. The use of these agents with MAVYRET is not recommended.

ADVERSE REACTIONS

Most common adverse reactions observed with MAVYRET:

- >10% of subjects: headache and fatigue

MAVYRET oral pellets are dispensed in unit-dose packets. Each packet contains 50 mg glecaprevir/20 mg pibrentasvir.

Please see full Prescribing Information, including BOXED WARNING, for additional information or visit http://www.rxabbvie.com.

Reference: 1. MAVYRET [package insert]. North Chicago, IL: AbbVie Inc.

abbvie

US-MAVY-230176 September 2023

MAVYRET®
glecaprevir/pibrentasvir
100 mg/40 mg tablets